Amita Gupta, MD, MHS

Professional Titles

• Chief, Division of Infectious Diseases, Johns Hopkins School of Medicine
• Faculty Co-chair, Johns Hopkins India Institute
• Director, Division of Infectious Diseases, Johns Hopkins School of Medicine

Primary Academic Title

Professor of Medicine

Background

Centers and Institutes

• Center for TB Research
• Clinical Global Health Education, Center for
• Global Health, Center for
• Gupta-Klinsky India Institute

LinkedIn

https://www.linkedin.com/in/amita-gupta-91720316/

Clinical Trial Keywords

Tuberculosis; HIV; PMTCT; Breastfeeding; Antiretroviral; MDR-TB; Maternal and Infant Health; TB preventive therapy; drug-resistant infections

Clinical Trials Summary

• ACTG 5300/IMPAACT 2003: Phase III, Open Label, Multi-center Trial: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
• HATHI: Hybrid Trial for Alcohol Reduction among People with TB and HIV in India
• Regional Prospective Observational Research for Tuberculosis (RePORT) International
• Regional Prospective Observational Research for Tuberculosis (RePORT) India
• IMPAACT 1078: Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings
• Hinduja-Hopkins TB Research Observational Clinical Database
• Impact of Diabetes on TB Treatment Outcomes:
• Dynamics and Immune Mechanisms of QFT Response in Close Contacts of TB Cases
• A Nanopore Biosensor for Leveling MTB  Antigens in Blood
• Pharmacokinetic Assessment of MDR-TB Drugs in the Treatment of TB Meningitis
• Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)
• Inflammasome Genetics and Tuberculosis Treatment Outcomes
• ACTG 5274: Phase IV, Open Label Strategy Trial: REMEMBER: Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens
• Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but Resistant to MTB Infection
• Host RNA Expression for Diagnosis and Monitoring of Pediatric TB in Africa and India
• Molecular Signatures of Tuberculosis-Diabetes Interaction
• Validation of Transcriptional Signature to Predict Active TB Disease among Advanced HIV Patients
• Residual Respiratory Impairment Following Pulmonary Tuberculosis
• Implementing the Comprehensive Unit-based Safety Program to Reduce Healthcare-Associated Sepsis in the Neonatal Intensive Care Unit in Pune, India
• Evaluating the Source of Neonatal Bloodstream Infections due to Classically Hospital Acquired Pathogens in the Neonatal Intensive Care Unit in Pune, India
• Gut Microbiota of HIV Infected Pregnant Women
• TREAT Asia Observational Database
• COVID analyses: JH CROWN Registry

Videos

• Johns Hopkins Division of Infectious Diseases
• Uniting for a Healthier India

Recent News Articles and Media Coverage

• With high unhealthy alcohol use and increased risk of TB, counseling holds a solution Scroll June 21, 2023
• Johns Hopkins Medicine-led consortium to receive up to $200 million to fight TB globally The HUB August 17,  2022
• India is a critical partner in addressing global public health challenges Economic Times June 8, 2022
• Amita Gupta Named Director of Johns Hopkins Medicine's Division of Infectious Diseases, Newswise Feb 3, 2022
• Johns Hopkins Students and Faculty Members Confront India's COVID-19 Crisis. Johns Hopkins Medicine. July 8, 2021
• 7 Lessons We've Learned from this Pandemic to Remember for the Next One. SELF. June 22, 2021
• India COVID-19 Outbreak Could 'Spread Around the World,' Expert Warns. International Business Times.  May 13, 2021
• Indian Students in US Anxious about COVID-19 Back Home. VOA News. May 13, 2021
• Johns Hopkins University Helping India Fight Covid Surge. CBS Baltimore. May 13, 2021
• Johns Hopkins expert Dr. Amita Gupta on India's covid 19 challenge & future preparedness options. Financial Express. May 12, 2021
• India's COVID-19 Disaster May Be Turning Into an Even Bigger Global Crisis. TIME. May 12, 2021
• How the US can help the COVID crisis in India. The Hill. May 4, 2021
• India's crushing COVID caseload the result of 'perfect storm' of factors, experts say. USA Today. April 28, 2021
• As COVID Crisis Unfolds in India, Johns Hopkins Rushes to Help. Johns Hopkins Hub. April 28, 2021
• A Bold New Chapter Begins for Hopkins and India. Johns Hopkins Hub. April 26, 2021
• Trump Briefly Leaves Hospital for Photo Op With Supporters. New York Magazine. October 4, 2020
• Johns Hopkins Researchers Publish COVID-19 'Prediction Model.' Johns Hopkins Medicine. September 23, 2020
• Study Shows Extent, Danger of TB Exposure, Part 1. Medical Daily. August 24, 2020
• International Johns Hopkins Study Says Broad Measures needed to Prevent TB Spread in India. Johns Hopkins Research Story Tip. August 6, 2020
• In Women with HIV, TB Preventive Therapy Poses Greater Risk in Pregnancy than Postpartum. NIH Press Release. October 2, 2019

Contact for Research Inquiries

1830 East Monument Street, Room 437
Baltimore, MD 21287

Phone: (410) 502-7696

Research Interests

TB in pregnancy, Antimicrobial Resistance, Diarrheal Diseases Epidemiology, Global Health, Infectious Diseases, Emerging Infections, COVID-19, TB, HIV and Co-Infection Care and Treatment Clinical Trials in India and Other Resource-Constrained Countries, Malnutrition and TB-HIV Coinfection in Adults and Children, Mother-to-Child Transmission Prevention, 

Lab Website

Amita Gupta Lab - Lab Website

• The Amita Gupta Lab focuses on drug trials to prevent and treat HIV, tuberculosis (TB) and other co-morbidities in adults, including pregnant women and children who reside in low-income settings. We also conduct cohort studies assessing HIV, inflammation and nutrition in international settings; TB in pregnancy; and risk factors for TB in India (CTRIUMPH). We collaborate with several faculty in the Center for TB Research, Division of Infectious Diseases and the School of Public Health.

Google Scholar

https://scholar.google.com/citations?user=WuXtPTgAAAAJ&hl=en&oi=ao

PubMed

https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Amita+Gupta&sort_order=desc

Selected Publications

• Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, Dawson R, Mave V, Gaikwad S, Sanchez J, Mendoza-Ticona A, Gonzales P, Comins K, Shenje J, Nerette Fontain S, Omozoarhe A, Mohapi L, Lalloo UG, Garcia Ferreira AC, Mugah C, Harrington M, Shah NS, Hesseling AC, Churchyard G, Swindells S, Gupta A; AIDS Clinical Trials Group (ACTG) A5300/International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) I2003 Protecting Households on Exposure to Newly Diagnosed Index Multidrug-resistant Tuberculosis Patients (PHOENIx) Feasibility Study Team. One-year incidence of tuberculosis infection and disease among household contacts of rifampin- and multi-drug resistant tuberculosis. Clin Infect Dis. 2023 May 25:ciad301. doi: 10.1093/cid/ciad301. Epub ahead of print. PMID: 37227925.

• Miner MD, Hatherill M, Mave V, Gray GE, Nachman S, Read SW, White RG, Hesseling A, Cobelens F, Patel S, Frick M, Bailey T, Seder R, Flynn J, Rengarajan J, Kaushal D, Hanekom W, Schmidt AC, Scriba TJ, Nemes E, Andersen-Nissen E, Landay A, Dorman SE, Aldrovandi G, Cranmer LM, Day CL, Garcia-Basteiro AL, Fiore-Gartland A, Mogg R, Kublin JG, Gupta A, Churchyard G. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV. 2022 Nov;9(11):e791-e800. doi: 10.1016/S2352-3018(22)00255-7. Epub 2022 Oct 11. Erratum in: Lancet HIV. 2022 Dec;9(12):e822. PMID: 36240834; PMCID: PMC9667733.

• Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. PMID: 31577875.

• Gupte AN, Kumar P, Araújo-Pereira M, Kulkarni V, Paradkar M, Pradhan N, Menon P, Chandrasekaran PD, Hanna LE, Yogendra Shivakumar SVB, Rockwood N, Du Bruyn E, Karyakarte R, Gaikwad S, Bollinger R, Golub J, Gupte N, Viswanathan V, Wilkinson RJ, Mave V, Babu S, Kornfeld H, Andrade BB, Gupta A. Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study. Eur Respir J. 2021 Oct 28:2100905. doi: 10.1183/13993003.00905-2021. Epub ahead of print. PMID: 34711538.

• Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, Schumock G, Nagy P, Gray JH, Malapati H, Ghobadi-Krueger M, Niessen TM, Kim BS, Hill PM, Ahmed MS, Dobkin ED, Blanding R, Abele J, Woods B, Harkness K, Thiemann DR, Bowring MG, Shah AB, Wang MC, Bandeen-Roche K, Rosen A, Zeger SL, Gupta A. Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. Ann Intern Med. 2021 Jan;174(1):33-41. doi: 10.7326/M20-3905. Epub 2020 Sep 22. Erratum in: Ann Intern Med. 2021 Jan;174(1):144. PMID: 32960645; PMCID: PMC7530643

• Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia JV, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE for the BRIEF TB/A5279 Study Team. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001-1011. DOI: 10.1056/NEJMoa1806808.

• Mave V, Chandanwale A, Kagal A, Khadse S, Kadam D, Bharadwaj R, Dohe V, Robinson ML, Kinikar A, Joshi S, Raichur P, McIntire K, Kanade S, Sachs J, Valvi C, Balasubramanian U, Kulkarni V, Milstone AM, Marbaniang I, Zenilman J, Gupta A. High Burden of Antimicrobial Resistance and Mortality Among Adults and Children With Community-Onset Bacterial Infections in India. J Infect Dis. 2017 Apr 15;215(8):1312-1320. doi: 10.1093/infdis/jix114. PMID: 28329303; PMCID: PMC5853545.

Honors

2018 Johns Hopkins School of Medicine 125th Anniversary "Living the Hopkins Mission" Honoree

Graduate Program Affiliations

• Division of Infectious Diseases

• International Health, Bloomberg School of Public Health

Memberships

• Infectious Diseases Society of America
• American Medical Association
• American Society of Tropical Medicine and Hygiene
• The International Union Against Tuberculosis and Lung Disease (The Union)

Professional Activities

• ACTG 5274, Reducing Early Mortality Among Patients with Advanced HIV Disease: A Randomized Strategy Trial Comparing the Safety and Efficacy of an Individualized Patient TB Treatment Approach to a Public Health Pre-emptive TB Treatment Approach in Resource-Limited Settings (REMEMBER), Vice Chair
• ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection, Vice Chair
• ACTG TB transformative Science Group, Member
• ACTG TB Transformative Science Group, Member
• Executive Committee, RePORT International, Member
• IeDEA TB working group, Chair
• IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings, Chair
• IMPAACT TB Scientific Committee, Vice Chair
• IMPAACT TB Scientific Committee, Vice Chair
• Indo-US Science and Technology Forum (IUSTTF), Governing Board Member
• JH COVID-19 CROWN registry research, Faculty
• Johns Hopkins India Institute, Faculty Co-chair
• NIAID Advisory Council, Member
• NIH/Indian Government TB Research Consortium (RePORT), Co-Chair
• PHOENIX ACTG A5300/IMPAACT 2003 feasibility study and MDR TB contact prophylaxis trial, Co-Chair
• Union Interest Group in Maternal-Infant TB working group, Member